{"filings":[{"id":471720,"accession_number":"0001193125-26-226968","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2026-05-15T20:31:27+00:00","items":["5.07"],"status":"ready","headline":"Prothena shareholders re-elect directors, ratify auditor, approve exec comp at 2026 AGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shane M. Cooke re-elected with 22,720,769 for, 11,923,467 against, 9,139 abstain.","Dennis J. Selkoe re-elected with 25,226,560 for, 9,420,544 against, 6,271 abstain.","KPMG ratified as 2026 auditor: 41,931,718 for, 82,815 against, 12,984 abstain (binding).","Non-binding say-on-pay approved: 32,303,076 for, 1,145,400 against, 1,204,899 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93625,"accession_number":"0001559053-26-000016","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Prothena Q1 net income $32.7M on $50M milestone; raises cash guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $32.7M ($0.60 diluted EPS) vs net loss of $60.2M ($1.12 loss) in Q1 2025.","Revenue $51.1M (vs $2.8M), primarily from $50M Novo Nordisk milestone for coramitug Phase 3 enrollment.","Updated FY2026 net cash used guidance to $18-23M (prior $50-55M); year-end cash ~$273M (midpoint), up $18M.","Initiated up to $100M share repurchase program; repurchased 788,990 shares for $7.3M through Q1.","PRX019 Phase 1 completed; potential $55M milestone if Bristol Myers Squibb advances by YE 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":51084000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105412,"accession_number":"0001559053-26-000009","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Prothena authorizes up to $100M share repurchase plan through Dec 31, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized repurchase of up to $100M of ordinary shares; plan expires Dec 31, 2026.","Company had $308.4M cash and no debt as of Dec 31, 2025.","Guidance (excluding buyback) expects ~$255M cash at year-end 2026.","Potential to earn up to $105M in clinical milestone payments from partners in 2026.","Repurchases are discretionary; no obligation to buy any shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105411,"accession_number":"0001559053-26-000003","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Prothena posts Q4 2025 net loss $21.6M; full-year loss $244.1M; 2026 cash burn guide $50-55M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $21.6M ($0.40 EPS) in Q4 vs $58.0M loss ($1.08 EPS) in Q4 2024; full-year loss $244.1M ($4.53 EPS).","Total revenue $21K in Q4 vs $2.1M a year ago; full-year revenue $9.7M vs $135.2M in 2024.","Cash & restricted cash $308.4M at Dec 31, 2025; no debt; shares outstanding ~53.8M.","2026 guidance: net cash used in ops $50-55M; year-end cash ~$255M; excludes up to $105M milestones.","Partners Roche, Novo Nordisk, BMS initiated Phase 3 trials for prasinezumab, coramitug, and BMS-986446."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":9684000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121689,"accession_number":"0001559053-25-000049","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Prothena board member Paula Cobb resigns effective Dec 31, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Paula Cobb notified Prothena of her resignation from the Board, effective December 31, 2025.","She will continue serving on the Board, Compensation Committee, and Audit Committee through that date.","Resignation is not due to any disagreement with the Company on operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121688,"accession_number":"0001559053-25-000047","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Prothena shareholders approve capital reduction to create distributable reserves","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["37.8M votes for, 46.7K against, 45.9K abstained at extraordinary general meeting on Nov 19, 2025.","Reduction of capital creates distributable reserves for potential future dividends or buybacks.","Meeting was held virtually; proposal described in proxy statement filed Oct 7, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121687,"accession_number":"0001559053-25-000042","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Prothena Q3 net loss $36.5M, nine-month loss $222.5M on charges; pipeline advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q3 2025 was $36.5M ($0.68/sh) vs $59.0M ($1.10/sh) in Q3 2024; nine-month loss $222.5M ($4.13/sh) vs $64.4M ($1.20/sh).","Revenue fell to $2.4M in Q3 2025 from $1.0M in Q3 2024; nine-month revenue $9.7M vs $133.0M primarily from BMS collaboration.","Cash and equivalents $331.7M; no debt. FY2025 guidance: net cash used $170-178M, year-end cash ~$298M midpoint.","Roche to initiate Phase 3 PARAISO prasinezumab trial for Parkinson's by end 2025; Novo Nordisk started Phase 3 CLEOPATTRA for coramitug in ATTR-CM.","EGM on Nov 19 to vote on share capital reduction to support potential 2026 share redemption program; up to $105M in clinical milestones by end 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":9663000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138368,"accession_number":"0001193125-25-189765","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Prothena PRX012 shows amyloid reduction but higher ARIA-E rates; seeks partnership","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 ASCENT: PRX012 400 mg achieved mean amyloid PET reduction to 27.47 CL at month 12.","ARIA-E rates at 400 mg (41.7%) and 200 mg (38.1%) exceeded those of FDA-approved anti-Aβ antibodies.","One death in 45 mg cohort deemed unrelated to study drug; injection site reactions low (4.1%).","Company plans to explore partnership to advance PRX012 and preclinical PRX012-TfR antibody."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138367,"accession_number":"0001193125-25-174061","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Prothena partner Novo Nordisk to advance coramitug to Phase 3 for ATTR-CM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Novo Nordisk plans Phase 3 program for coramitug in ATTR-CM, start expected in 2025.","Prothena eligible for up to $1.2B in milestones, $100M received to date.","Clinical milestone payment triggered when prespecified enrollment criteria met in Phase 3.","Coramitug is a potential first-in-class amyloid depleter antibody."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138366,"accession_number":"0001559053-25-000029","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Prothena Q2 net loss $125.8M; prasinezumab to enter Phase 3 by end 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $125.8M vs income $66.9M last year; includes $32.6M restructuring charge and $44.9M non-cash tax allowance.","Revenue $4.4M, down from $132.0M YoY; cash $372.3M with no debt; FY 2025 cash burn guidance $170-178M.","Partner Roche plans Phase 3 start for prasinezumab in early Parkinson's by end 2025; peak sales potential >$3B.","Initial Phase 1 data for PRX012 in Alzheimer's expected August 2025; up to $105M milestones possible in 2026.","Prothena to hold EGM by year-end to vote on share capital reduction for potential share redemption program."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":7248000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138365,"accession_number":"0001193125-25-169367","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Prothena Biosciences enters employment agreements with CFO, COO, CSO; base salaries set at $518K-$604K","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CFO Tran Nguyen base $603,792 (50% bonus target); COO Brandon Smith $544,201 (50%); CSO Wagner Zago $518,000 (40%).","Severance without cause or for good reason: 100% base salary, 100% target bonus, up to 12 months COBRA.","Change-in-control severance: 150% base, 150% target bonus, up to 18 months COBRA plus equity acceleration.","Agreements memorialize benefits consistent with existing severance plan; no change in roles or compensation levels."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155815,"accession_number":"0001193125-25-142725","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["2.05","5.02"],"status":"ready","headline":"Prothena cuts 63% of workforce, expects $16-20M severance costs; two C-suite execs to leave Aug 1","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Workforce reduction of ~63% to cut operating costs; substantially complete by Q4 2025.","Expected severance and benefits $16-20M plus non-cash stock option acceleration.","Chief Regulatory Officer Carol D. Karp and Chief People Officer David A. Ford to depart Aug 1, 2025.","Follows May 23 decision to discontinue birtamimab development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155814,"accession_number":"0001193125-25-141098","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Roche to advance prasinezumab to Phase III for Parkinson’s; Phase IIb data missed primary endpoint","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Partner Roche advancing prasinezumab into Phase III for early-stage Parkinson’s disease.","Phase IIb PADOVA study missed statistical significance on primary endpoint but showed positive trends in motor progression.","Open-label extension data suggest sustained clinical benefit over longer treatment periods.","First biomarker evidence from PADOVA indicates impact on underlying disease biology.","Over 10 million people affected globally; potential first disease-modifying treatment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155813,"accession_number":"0001193125-25-125881","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Prothena's Phase 3 AFFIRM-AL trial for birtamimab fails; development halted; workforce reduction planned","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 AFFIRM-AL did not meet primary endpoint of all-cause mortality (HR=0.915, p=0.7680); secondary endpoints also missed.","Birtamimab development discontinued; open-label extension stopped.","Company to substantially reduce workforce and operating expenses; further update expected in June 2025.","Birtamimab was generally safe and well-tolerated, consistent with prior safety profile.","Upcoming data: PRX012 Phase 1 ASCENT (Alzheimer's) in August; partner updates from Roche, Novo Nordisk, BMS in 2025-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155812,"accession_number":"0001559053-25-000025","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Prothena shareholders approve 2M share increase to LTIP, re-elect all directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved an amendment increasing shares under the 2018 LTIP by 2,000,000, effective May 13, 2025.","Directors Paula Cobb, Lars Ekman, and Gene Kinney re-elected to terms through 2028; Kinney had 9.7M against.","Advisory vote on named executive officer compensation passed with 34.7M for vs 11.2M against.","Ratification of KPMG as independent auditor for FY2025 passed with 50.3M for.","Amendment sets overall share limit to 13,100,000 plus prior plan carryover shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155811,"accession_number":"0001559053-25-000022","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Prothena Q1 net loss $60.2M, cash $418.8M; AFFIRM-AL data due Q2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $60.2M ($1.12/share) vs $72.2M ($1.34/share) year ago; revenue $2.8M (from BMS collaboration).","Cash $418.8M at quarter end; FY2025 net cash burn guidance $168-175M, ending cash ~$301M.","Phase 3 AFFIRM-AL (birtamimab) topline results expected Q2 2025; SPA with FDA, primary endpoint all-cause mortality.","Multiple PRX012 Phase 1 readouts expected from mid-2025; Roche to decide prasinezumab next steps mid-year.","Novo Nordisk's coramitug Phase 2 for ATTR-CM completes enrollment; results expected H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":2828000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174283,"accession_number":"0001559053-25-000003","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Prothena reports FY2024 net loss $122.3M; cash $472.2M; AFFIRM-AL topline expected Q2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss per share Q4 $1.08, FY2024 $2.27; total revenue FY2024 $135.2M (up from $91.4M prior year).","Cash $472.2M at Dec 31, 2024, no debt; 2025 guidance: net cash burn $168-175M, year-end cash ≈$301M.","Confirmatory Phase 3 AFFIRM-AL (birtamimab) topline results expected Q2 2025; SPA with FDA, primary endpoint all-cause mortality.","PRX012 Phase 1 ASCENT readouts starting mid-2025; BMS started Phase 2 for BMS-986446; $80M received for PRX019 license.","Roche's prasinezumab Phase 2b PADOVA missed primary endpoint but showed trends; Roche to discuss next steps with health authorities."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":135157000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191231,"accession_number":"0001193125-24-286866","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2024-12-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Oleg Nodelman resigns from Prothena board effective Dec 31, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Oleg Nodelman resigned from the Board effective Dec 31, 2024, to focus on other endeavors.","He served on the Compensation Committee and Nominating and Corporate Governance Committee.","Resignation was not due to any disagreement with the company's operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191230,"accession_number":"0001559053-24-000034","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Prothena reports Q3 net loss of $59M on $1M revenue, cash at $520M; pipeline readouts expected in 2024-2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $59.0M ($1.10 per share) vs net income of $21.9M ($0.38 diluted) in Q3 2023; revenue fell to $1.0M from $84.9M.","Cash and restricted cash $520.1M as of Sep 30 2024; full-year net cash use guidance reaffirmed at $148-$160M.","Expects topline results from Phase 2b PADOVA (prasinezumab) in 4Q2024 and Phase 3 AFFIRM-AL (birtamimab) in 1H2025.","Phase 1 ASCENT trials (PRX012) for Alzheimer's disease to report multiple readouts starting mid-2025.","Appointed Chad J. Swanson, Ph.D., as Chief Development Officer in September 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":133034000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207693,"accession_number":"0001559053-24-000028","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2024-09-27T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Prothena CMO Hideki Garren departs; Chad Swanson appointed Chief Development Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Hideki Garren, M.D., Ph.D., resigns as Chief Medical Officer effective Sept 27, 2024, to lead global product development at a large pharma.","Chad Swanson, Ph.D., promoted to Chief Development Officer; will lead clinical development and medical functions.","Swanson joined Prothena in Jan 2023 from Eisai, where he led the lecanemab program for early Alzheimer's disease.","Prothena will initiate a search for a new Chief Medical Officer.","Swanson will join the executive leadership team and report to CEO Gene Kinney."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207692,"accession_number":"0001559053-24-000023","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Prothena Q2 net income $66.9M; BMS licenses PRX019 for $80M; year-end cash guidance raised to $468M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net income $66.9M (diluted EPS $1.22) vs net loss $54.6M in Q2 2023; revenue $132M vs $4M.","BMS obtained exclusive global license for PRX019 for $80M upfront; potential milestones up to $617.5M.","Year-end cash guidance raised to ~$468M from $405M; net cash used guidance reduced to $148-160M.","Topline results expected: prasinezumab Phase 2b (2H 2024), birtamimab Phase 3 (4Q24-2Q25), coramitug Phase 2 (1H25).","Cash and restricted cash $565M as of June 30, 2024; no debt; ~53.8M shares outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":132064000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225166,"accession_number":"0001559053-24-000019","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2024-05-28T23:59:59+00:00","items":["1.01","8.01"],"status":"ready","headline":"Prothena licenses PRX019 to BMS for $80M upfront; milestones up to $617.5M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront payment of $80 million from BMS; eligible for additional development and regulatory milestones up to $242.5M.","Sales milestones up to $375M upon achieving certain annual net sales thresholds.","Tiered royalties on worldwide net sales ranging from high single-digit to high teen percentages.","Prothena obligated to run Phase 1 for PRX019; BMS may elect to take over the trial.","Research term under Master Collaboration Agreement expired on May 24, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225165,"accession_number":"0001559053-24-000017","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Prothena shareholders approve 2M share increase under LTIP at AGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["LTIP amendment adding 2,000,000 ordinary shares approved with 36.9M for, 8.9M against.","Directors Collier, Cooke, Dunn, Welch re-elected to board until 2027.","KPMG ratified as independent auditor for FY 2024 with 49.4M for, 63,084 against.","Non-binding advisory vote on named executive officer compensation passed with 45.3M for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225164,"accession_number":"0001559053-24-000012","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Prothena Q1 net loss $72.2M ($1.34/sh); cash $548.7M; guides FY 2024 cash burn $208-225M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $72.2M vs $46.9M YoY; revenue $0.1M vs $2.2M; R&D expenses $64.1M vs $44.8M.","Cash, equivalents & restricted cash $548.7M (no debt); expects ~$405M year-end 2024.","Phase 3 AFFIRM-AL (birtamimab) topline data expected 4Q24–2Q25; Phase 1 PRX012 update in 2024.","Bristol Myers Squibb initiated Phase 2 for BMS-986446 (tau antibody) in early Alzheimer’s.","Daniel G. Welch appointed independent director and Chair Designate; David Ford named Chief People Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":50000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244391,"accession_number":"0001559053-24-000005","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2024-02-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Prothena appoints Daniel G. Welch as director and Chair Designate","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded to add Daniel G. Welch as director effective Feb 21, 2024; to be proposed as Chair at next AGM.","Welch granted option for 132,000 ordinary shares, vesting over five years at the Feb 21 closing price.","Annual cash retainer of $90,000 as Chair Designate and future Chair, plus standard non-employee director compensation.","Welch will enter standard indemnification agreement; no material interest in any related transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244390,"accession_number":"0001559053-24-000003","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2024-02-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Prothena Q4 2023 net loss $67.5M; cash $621M; guides 2024 cash burn ~$208-225M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 $67.5M ($1.26 loss per share) vs net income $6.3M Q4 2022; full year loss $147.0M.","Total revenue Q4 $0.3M (vs $49.9M Q4 2022); full year $91.4M including $55M BMS milestone.","Cash, equivalents & restricted cash $621M at Dec 31, 2023; no debt. 2024 cash use guidance $208-225M.","Phase 1 PRX012 (Alzheimer's) data update expected 2024; partner BMS to advance BMS-986446 to Phase 2 in 1H2024.","AFFIRM-AL birtamimab topline (Mayo Stage IV AL amyloidosis) expected between 4Q2024-2Q2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":91370000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244389,"accession_number":"0001193125-24-003972","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Prothena reports $621M cash at year-end 2023; pipeline updates on PRX012, PRX123, birtamimab","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, cash equivalents, and restricted cash ~$621M as of Dec 31, 2023; sufficient capital beyond ongoing trials.","PRX012 (Alzheimer's): Phase 1 data supports once-monthly dosing; dose escalation to 200-400mg underway.","PRX123 (Alzheimer's vaccine): IND cleared and Fast Track designation; Phase 1 timeline update expected in 2024.","Birtamimab (AL amyloidosis): Phase 3 AFFIRM-AL enrollment on track; topline results expected 4Q24-2Q25.","Partnered programs with BMS, Roche, Novo Nordisk remain on track; BMS-986446 moving to Phase 2 in 1H24."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261819,"accession_number":"0001559053-23-000031","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Prothena reports Q3 net income of $21.9M; revenue surges to $84.9M on BMS license","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $21.9M ($0.38 diluted EPS) vs net loss of $45.8M in Q3 2022; first nine months net loss of $79.6M.","Revenue of $84.9M, primarily from $72.9M collaboration revenue from BMS tau license including $55M option fee.","Cash and restricted cash $673.1M at Sept 30, 2023; guidance for year-end ~$600M.","Upcoming milestones: PRX012 Phase 1 data by year-end 2023; AFFIRM-AL topline in 2024; prasinezumab Phase 2b in 2024.","R&D expenses rose to $57.9M (+45% YoY) due to higher clinical trial costs."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":91054000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278997,"accession_number":"0001559053-23-000025","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Prothena Q2 net loss $54.6M, revises FY cash guidance up to ~$600M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $54.6M ($1.03/share) vs $41.2M loss in Q2 2022; revenue $4.0M (up from $1.3M).","Cash, equivalents $661.3M at June 30; year-end cash guidance raised to ~$600M midpoint from $512M.","Bristol Myers Squibb exercised $55M option for worldwide rights to PRX005 (anti-tau) in July 2023.","PRX012 Phase 1 topline data expected year-end 2023; IND filing for PRX123 dual vaccine expected year-end.","Billy Dunn (former FDA Office of Neuroscience Director) added to Board."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":6188000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278996,"accession_number":"0001559053-23-000021","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2023-07-10T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Prothena expands BMS tau collaboration to global license; $55M fee, milestones up to $562.5M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["BMS exercises option to convert US-only tau license to global; Prothena receives $55M exercise fee.","Milestone payments increased from up to $465M to up to $562.5M under global agreement.","Prothena eligible for up to $15M in CMC expense reimbursement.","Tiered royalties on net sales unchanged; term runs product-by-product until end of royalty term.","Global license supersedes prior US-only tau license dated July 30, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297325,"accession_number":"0001193125-23-149386","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2023-05-19T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Prothena shareholders approve 2M share increase in LTIP; Nodelman re-elected with significant opposition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to 2018 LTIP, increasing authorized shares by 2,000,000 effective May 16, 2023.","Director re-election: Kim, Kinney, Nodelman, Selkoe elected; Nodelman received 11.5M against votes (~24.6%).","Ratified KPMG as independent auditor for 2023 in binding vote (49.9M for, 64.8k against).","Non-binding say-on-pay advisory vote approved with 45.2M for, 358.6k against, 1.2M abstain.","Fourth Amendment to LTIP filed as Exhibit 10.1, raising Overall Share Limit to 9,100,000 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297324,"accession_number":"0001559053-23-000019","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2023-05-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Prothena appoints Dr. William H. Dunn, Jr. to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. William H. Dunn, Jr., M.D. appointed to Board effective May 16, 2023.","Board size increased to accommodate the new appointment.","Dr. Dunn will receive standard non-employee director compensation per 2023 proxy.","He will enter into the Company's standard Deed of Indemnification.","No arrangements or understandings with others led to his selection; no reportable interests."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297323,"accession_number":"0001559053-23-000014","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Prothena Q1 net loss widens to $46.9M; pipeline progress with PRX012, PRX005 data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $46.9M ($0.89 per share) vs $36.3M ($0.78) in Q1 2022; revenue $2.2M from BMS collaboration.","Cash position $688.4M; FY 2023 guidance: net cash used $213-229M, year-end cash ~$512M.","PRX012 preclinical data at AD/PD showed 20-fold higher affinity vs lecanemab; PRX005 Phase 1 SAD met safety objective.","Key milestones: PRX012 topline data year-end 2023; birtamimab Phase 3 AFFIRM-AL topline in 2024.","R&D expenses rose to $44.8M from $27.3M driven by clinical trial costs."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":2169000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297322,"accession_number":"0001559053-23-000010","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2023-04-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Sanjiv K. Patel resigns from Prothena board effective July 1, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Patel resigned from the Board and Compensation Committee, effective July 1, 2023.","He will continue to serve on the Board and Committee through July 1, 2023.","Resignation was not due to any disagreement with the Company on operations, policies, or practices.","No replacement director or committee member has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317678,"accession_number":"0001559053-23-000007","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Prothena confirms no cash or securities at Silicon Valley Bank","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company states it does not hold any cash deposits or securities at Silicon Valley Bank.","Disclosure made on March 10, 2023, amid SVB's collapse and industry exposure concerns.","No financial exposure to SVB's receivership; investor risk from bank failure avoided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317677,"accession_number":"0001559053-23-000002","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2023-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Prothena reports Q4 net income $6.3M, full year net loss $116.9M; provides 2023 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 revenue $49.9M (incl. $40M Novo Nordisk milestone); full year revenue $53.9M vs $200.6M in 2021.","Cash, cash equivalents and restricted cash $712.6M at Dec 31, 2022; no debt.","2023 guidance: net cash used in operating/investing $213-229M; year-end cash ~$512M.","PRX012 Phase 1 topline data expected year-end 2023; PRX005 Phase 1 MAD topline also year-end 2023.","Birtamimab Phase 3 AFFIRM-AL topline data expected 2024; prasinezumab Phase 2b topline 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":53905000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335935,"accession_number":"0001193125-22-307391","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2022-12-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Prothena launches $172.4M public offering of 3.25M ordinary shares at $53.11/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwriters agreed to buy 3,250,000 ordinary shares at $53.11 per share; 30-day option for up to 487,500 additional shares.","Net proceeds expected to be approximately $172.4 million after discounts and expenses, assuming no underwriter option exercise.","Offering expected to close on December 19, 2022; lock-up agreements for directors, officers, and certain shareholders for 90 days.","Proceeds intended for general corporate purposes; underwriting agreement includes customary indemnification provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335934,"accession_number":"0001559053-22-000049","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2022-11-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Prothena earns $40M milestone from Novo Nordisk for ATTR cardiomyopathy drug advance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$40 million milestone payment from Novo Nordisk triggered by continued Phase 2 study of NNC6019 for ATTR cardiomyopathy.","Total potential milestone payments up to $1.2 billion; $100 million earned to date including this payment.","Novo Nordisk acquired full worldwide rights to ATTR amyloidosis pipeline from Prothena in July 2021.","Phase 2 study addresses high unmet need in moderate to advanced ATTR amyloidosis with risk of early mortality."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335933,"accession_number":"0001559053-22-000046","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Prothena Q3 2022 net loss $45.8M vs income $109.2M y/y; cash $497M; cuts FY22 net cash burn guidance to $108-120M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $45.8M ($0.97 per share) vs net income $109.2M ($2.13 diluted EPS) in Q3 2021.","Total revenue $1.5M vs $139.2M y/y, primarily due to prior year BMS and Novo Nordisk milestones.","Cash and restricted cash $497.0M; no debt; shares outstanding ~48.4M as of Oct 26.","Updated FY2022 net cash burn guidance $108-120M (down from $120-132M); year-end cash ~$522M.","R&D expenses $39.9M in Q3 2022 vs $18.0M y/y, driven by manufacturing and clinical costs."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":3982000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335932,"accession_number":"0001559053-22-000040","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2022-10-31T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Prothena enters sublease for 31,157 sq ft in Brisbane, CA; rent starts July 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PBI subleases ~31,157 sq ft from Arcus Biosciences at 1800 Sierra Point Parkway, Brisbane, CA.","Term ends Sep 30, 2028; rent begins Jul 1, 2023 with monthly base rent ~$241,467 in year 1.","Rent increases ~3.5% annually; first six months rent abated.","Improvement allowance of ~$9.35M from sublandlord for construction and prep.","Standby letter of credit ~$860,360 posted to secure obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353347,"accession_number":"0001559053-22-000037","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2022-09-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Prothena appoints Helen S. Kim to board of directors, effective Aug 30, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board size increased with appointment of Helen S. Kim as director.","Ms. Kim will receive standard non-employee director fees and equity compensation as disclosed in 2022 proxy.","She will enter company's standard indemnification agreement; no arrangements with other persons."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353346,"accession_number":"0001559053-22-000030","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2022-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Prothena Q2 2022 net loss $41.2M vs net income $27.6M a year ago; cash $510.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $41.2M ($0.88 loss per share) vs net income of $27.6M ($0.58 diluted EPS) in Q2 2021.","Total revenue $1.3M from BMS collaboration, down from $60.1M in Q2 2021 which included Roche revenue.","Cash and restricted cash $510.1M at June 30, 2022; no debt.","FDA Fast Track granted for PRX012 (anti-Aβ antibody for Alzheimer's); topline Phase 1 data for PRX005 expected by year-end 2022.","Full-year 2022 net cash used in operations and investing expected $120-$132M; year-end cash ~$454M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":2465000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371054,"accession_number":"0001559053-22-000026","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2022-05-20T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Shareholders approve 2M share increase to Prothena's 2018 LTIP at AGM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Re-elected directors Cobb, Ekman, Patel with >93% votes cast in favor.","Approved 2,000,000 additional ordinary shares under 2018 LTIP (36.4M for, 5.6M against).","Ratified KPMG as auditor for FY2022 and approved exec compensation (non-binding).","Renewed board authority to allot/issue ordinary shares (including without pre-emption rights) until May 2027.","Say-on-pay frequency set at every year (40.7M votes for one year)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371053,"accession_number":"0001559053-22-000021","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Prothena Q1 net loss $36.3M; PRX012 gets Fast Track, Phase 1 started","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $36.3M ($0.78 per share) vs $36.7M loss ($0.91) in Q1 2021; revenue $1.2M.","Cash and restricted cash $544.3M at quarter end; no debt; net cash used in ops/investing $37.4M.","PRX012 initiated Phase 1 SAD study, received FDA Fast Track for Alzheimer's disease.","R&D expense $27.3M (up 29% YoY) driven by birtamimab, PRX012, PRX005 programs.","FY 2022 guidance: net cash outflow $120-132M, net loss $154-170M, year-end cash ~$454M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":1153000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371052,"accession_number":"0001559053-22-000017","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2022-04-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Prothena's PRX012 granted FDA Fast Track designation for Alzheimer's treatment","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA Fast Track designation for PRX012, a next-generation anti-amyloid beta antibody for Alzheimer's.","PRX012 is currently in Phase 1 clinical study; designed for subcutaneous administration.","Fast Track may enable more frequent FDA interactions and eligibility for Accelerated Approval and Priority Review.","Prothena CEO Gene Kinney stated PRX012 has potential to lead a paradigm shift in Alzheimer's treatment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390056,"accession_number":"0001559053-22-000014","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2022-03-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA clears IND for Prothena's PRX012 subcutaneous anti-Aβ antibody; Phase 1 SAD study initiated","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND for PRX012, a potential best-in-class anti-amyloid beta antibody for Alzheimer's disease.","Phase 1 single ascending dose study in healthy volunteers and AD patients has started; MAD study expected by year-end 2022.","PRX012 designed for subcutaneous dosing with high binding potency; preclinical data show plaque occupancy at low doses.","Prothena expects PRX012 to serve as a foundational anti-Aβ treatment with convenient administration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390055,"accession_number":"0001559053-22-000012","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2022-03-25T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Prothena directors/officers adopt 10b5-1 plans for 458,174 expiring options","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Options granted in Jan/Mar/Apr 2013 expire in Jan/Mar/Apr 2023; cover 458,174 shares (<1% of outstanding) with exercise prices $6.41-$6.73 per share.","Directors and executive officers adopted Rule 10b5-1 trading plans to exercise/sell these expiring options.","Plans allow orderly disposition of options expiring in 2023; transactions will be reported to the SEC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390054,"accession_number":"0001559053-22-000003","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2022-02-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Prothena reports FY2021 net income of $67M; cash $580M; pipeline advances with SPA and partnerships","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2021 revenue $200.6M (vs $0.9M in 2020); net income $67.0M vs net loss $111.1M in 2020.","Cash and restricted cash $580.4M at Dec 31, 2021, no debt; raised $175M in equity in 2021.","Received $80M BMS option for PRX005, $60M Roche milestone for prasinezumab, $60M upfront from Novo Nordisk for ATTR.","Reached SPA agreement with FDA for confirmatory Phase 3 AFFIRM-AL study of birtamimab in AL amyloidosis; Phase 1 of PRX005 initiated.","2022 guidance: net cash used $120-132M; expected net loss $154-170M; ending cash ~$454M."],"consensus_eps_estimate":null,"consensus_eps_actual":1.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":200577000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":408061,"accession_number":"0001193125-21-366358","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2021-12-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Prothena enters $250M at-the-market equity distribution agreement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with Piper Sandler, Stifel, Cantor Fitzgerald, RBC Capital Markets, and JMP Securities.","Company may sell up to $250M of ordinary shares from time to time via ATM offerings.","Agents receive up to 3% commission on gross proceeds; company may set minimum sale price.","Offering terminates upon sale of all shares or earlier termination by either party.","Company is not obligated to sell any shares under the agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":408060,"accession_number":"0001559053-21-000043","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2021-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Prothena reports Q3 net income of $109.2M vs loss; revenue $139.2M on partner payments","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net income $109.2M ($2.13 diluted EPS) vs net loss $30.6M a year ago; 9-month net income $100.2M.","Revenue $139.2M, driven by $78.5M BMS option for PRX005 US license and $60.7M IP sale to Novo Nordisk.","Cash, equivalents and restricted cash $601.5M at Sept 30, 2021; no debt.","Updated FY2021 guidance: year-end cash ~$575M, net cash from ops/investing $85-95M, net income $50-60M.","Appointed Tran Nguyen as CFO and Chief Strategy Officer; Brandon Smith as COO."],"consensus_eps_estimate":null,"consensus_eps_actual":2.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":199405000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":523008825.56829506,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-11-04T23:59:59+00:00|408060"}